Skip to content

EV / EBITDA at other companies

Merck & Co. logo
Merck & Co.MRK
23.1×+11.7×
Zoetis logo
ZoetisZTS
14.4×-5.9×
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
21.6×
Neogen logo
NeogenNEOG
28.3×-7.1×
Balchem logo
BalchemBCPC
20.7×-2.0×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
1,820.6×

Other financials

Income statement

See full
Revenue$383.5M+10.3%
Gross profit$125.7M+20.2%
Operating income$44.7M+33.2%
Net income$24.0M+15.1%
EPS (diluted)$0.59+15.7%

Balance sheet

See full
Cash & equivalents$54.9M-9.0%
Total debt$32.3M+27.8%
Total equity$361.8M+36.0%
Total assets$1.4B+9.7%

Cash flow

See full
Operating cash flow$16.2M-62.4%
CapEx$15.3M+97.7%
Free cash flow$890.0K-97.5%

Valuation

See full
Market cap$1.27B+31.4%
Enterprise value$1.25B+33.9%
P/E13.4×-17.1×
P/S0.9×0.0×

Profitability

See full
Gross margin32.5%+0.9pp
Operating margin12%+4.0pp
Net margin6.3%+3.7pp
FCF margin0.9%-3.3pp

Returns & leverage

See full
Return on equity30.3%+18.5pp
Debt / equity0.1×0.0×
Current ratio3.2×+0.3×

Where this comes from

Calculated from Phibro Animal Health’s reported figures.

Based on the most recent quarter.

The official record: Phibro Animal Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phibro Animal Health's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phibro Animal Health's EV / EBITDA?
Phibro Animal Health (PAHC) reported EV / EBITDA of 9.6× in Q1 2026.
How has Phibro Animal Health's EV / EBITDA changed year-over-year?
Phibro Animal Health's EV / EBITDA increased by 59.5% year-over-year, from 6× to 9.6×.
What is the long-term trend for Phibro Animal Health's EV / EBITDA?
Over 4 years (2021 to 2025), Phibro Animal Health's EV / EBITDA has grown at a -12.5% compound annual growth rate (CAGR), from 10.9× to 6.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.